Avery Therapeutics, Inc. is a startup company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle. Avery's lead product, MyCardia, is a tissue-engineered heart graft developed to treat heart failure and is currently in the pre-clinical development phase.